Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptor pathways (GPCRs). We are designing proprietary novel small molecule therapeutic candidates with the intent of developing best/first in class therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using our integrated drug discovery platform, medicinal chemistry expertise and deep understanding of GPCR biology. Liminal BioSciences has its registered office in Belleville, Ontario and operations in Laval, Quebec, Canada, and Cambridge, UK.
Address
LavalQuebec
Canada